Cancer Genetics Rating Reiterated by Cantor Fitzgerald (CGIX)
Cancer Genetics (NASDAQ:CGIX)‘s stock had its “buy” rating restated by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Thursday. They currently have a $25.00 price target on the stock, down from their previous price target of $30.00. Cantor Fitzgerald’s target price would indicate a potential upside of 153.81% from the company’s current price.
Cancer Genetics (NASDAQ:CGIX) traded down 7.61% on Thursday, hitting $9.10. 67,721 shares of the company’s stock traded hands. Cancer Genetics has a 1-year low of $8.48 and a 1-year high of $23.25. The stock’s 50-day moving average is $10.4 and its 200-day moving average is $13.77. The company’s market cap is $84.5 million.
Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.13. The company had revenue of $3.20 million for the quarter, compared to the consensus estimate of $2.13 million. Analysts expect that Cancer Genetics will post $-1.33 EPS for the current fiscal year.
Cancer Genetics, Inc (NASDAQ:CGIX) is an early-stage, diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.